VYNE Therapeutics (NASDAQ:VYNE) and Yarrow Bioscience have entered into a definitive all-stock merger agreement, with the combined company expected to operate under the name Yarrow Bioscience and trade on Nasdaq under the ticker YARW.
The merger, which is part of a strategic move to consolidate resources and expand clinical development, includes pre-closing financings of approximately $200 million led by RTW Investments.
This financing will provide the combined company with sufficient cash to fund operations into 2028.
In addition to the merger, VYNE Therapeutics plans to declare a pre-closing cash dividend ranging from $14.5 million to $16.5 million to its stockholders before the merger closes.
The merger strengthens Yarrow Bioscience’s financial position and sets the stage for the continued development of its lead program, YB-101 (GS-098), which will advance into a U.S.-based Phase 1b/2b trial in H1 2026.
Phase 1b data for YB-101 is expected by H2 2027.
A Phase 1 TED trial is also ongoing in China through Yarrow's partner, GenSci.
This merger positions the newly formed Yarrow Bioscience to focus on its clinical programs and accelerate its growth in the biotechnology sector.